We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Starpharma Holdings is a biotechnology business based in Australia. Starpharma Holdings shares (SPL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Starpharma Holdings has a trailing 12-month revenue of around $3.4 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $0.62 - $1.61 |
|---|---|
| 50-day moving average | $0.7789 |
| 200-day moving average | $1.0264 |
| Target price | $1.44 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.044 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.72
| 1 week (2022-06-16) | 8.27% |
|---|---|
| 1 month (2022-05-26) | -5.88% |
| 3 months (2022-03-25) | -21.74% |
| 6 months (2021-12-24) | -44.62% |
| 1 year (2021-06-25) | -54.29% |
|---|---|
| 2 years (2020-06-26) | -38.20% |
| 3 years (2019-06-26) | -47.64% |
| 5 years (2017-06-23) | -2.70% |
| Revenue TTM | $3.4 million |
|---|---|
| Gross profit TTM | $-13,715,000 |
| Return on assets TTM | -15.96% |
| Return on equity TTM | -28.44% |
| Profit margin | 0% |
| Book value | 0.135 |
| Market capitalisation | $261.4 million |
TTM: trailing 12 months
We're not expecting Starpharma Holdings to pay a dividend over the next 12 months.
Over the last 12 months, Starpharma Holdings 's shares have ranged in value from as little as $0.62 up to $1.61. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Starpharma Holdings 's is 1.3967. This would suggest that Starpharma Holdings 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
Steps to owning and managing Endeavour Group shares.
